H6PD

Across TCGA pan-cancer cohorts, H6PD Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated H6PD data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher H6PD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated H6PD expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

BRCA, SCLC, and SARC are the cancer types where H6PD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.122	0.579	<.001	16	view →
SCLC	OS	Median	All	0.201	0.720	<.001	12	view →
SARC	DFS	Median	All	0.124	0.595	.005	9	view →
LIHC	DFS	Median	III,IV	0.040	0.361	<.001	6	view →
UCEC	DFS	Median	All	0.967	0.830	.038	2	view →
STAD	DFS	Median	III,IV	1.000	0.312	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

H6PD–BRCA (OS)

Open the BRCA breakdown →